Concepts (326)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 17 | 2024 | 605 | 6.070 |
Why?
|
| Dermatology | 6 | 2024 | 42 | 3.440 |
Why?
|
| Skin | 15 | 2024 | 595 | 3.360 |
Why?
|
| Photochemotherapy | 10 | 2024 | 101 | 3.280 |
Why?
|
| Acne Vulgaris | 5 | 2024 | 35 | 2.830 |
Why?
|
| Education, Medical | 4 | 2024 | 246 | 2.390 |
Why?
|
| Keratosis, Actinic | 4 | 2024 | 13 | 1.990 |
Why?
|
| Melanoma | 6 | 2024 | 482 | 1.940 |
Why?
|
| Skin Diseases | 6 | 2024 | 175 | 1.840 |
Why?
|
| Photosensitizing Agents | 9 | 2024 | 52 | 1.760 |
Why?
|
| Dermatitis, Atopic | 3 | 2022 | 62 | 1.430 |
Why?
|
| Mohs Surgery | 4 | 2024 | 26 | 1.420 |
Why?
|
| Internship and Residency | 4 | 2021 | 1086 | 1.420 |
Why?
|
| Nevus, Pigmented | 2 | 2023 | 53 | 1.420 |
Why?
|
| Pigmentation Disorders | 2 | 2019 | 13 | 1.270 |
Why?
|
| Nevus | 3 | 2023 | 17 | 1.240 |
Why?
|
| Skin Aging | 3 | 2024 | 31 | 1.210 |
Why?
|
| Scalp Dermatoses | 2 | 2019 | 10 | 1.200 |
Why?
|
| Humans | 69 | 2024 | 92352 | 1.050 |
Why?
|
| Laser Therapy | 6 | 2024 | 151 | 1.010 |
Why?
|
| Phototherapy | 2 | 2016 | 35 | 1.010 |
Why?
|
| Patient Education as Topic | 3 | 2024 | 369 | 0.980 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2024 | 1090 | 0.970 |
Why?
|
| Sunscreening Agents | 1 | 2024 | 8 | 0.890 |
Why?
|
| Melanosis | 1 | 2024 | 5 | 0.870 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2023 | 14 | 0.830 |
Why?
|
| Interleukin-4 | 2 | 2021 | 131 | 0.810 |
Why?
|
| Rejuvenation | 3 | 2024 | 21 | 0.810 |
Why?
|
| Aminolevulinic Acid | 3 | 2019 | 22 | 0.790 |
Why?
|
| Vitamin A | 1 | 2022 | 28 | 0.790 |
Why?
|
| Rhinitis, Allergic | 1 | 2022 | 46 | 0.760 |
Why?
|
| Skin Diseases, Genetic | 1 | 2022 | 5 | 0.750 |
Why?
|
| Mouth Mucosa | 2 | 2019 | 68 | 0.750 |
Why?
|
| Urticaria | 1 | 2022 | 15 | 0.750 |
Why?
|
| Sebaceous Gland Neoplasms | 2 | 2019 | 7 | 0.730 |
Why?
|
| Exanthema | 1 | 2022 | 41 | 0.720 |
Why?
|
| Research Subjects | 1 | 2021 | 73 | 0.690 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 356 | 0.680 |
Why?
|
| Teaching Materials | 1 | 2020 | 14 | 0.680 |
Why?
|
| Drug Eruptions | 2 | 2021 | 31 | 0.680 |
Why?
|
| Dermatologists | 1 | 2020 | 2 | 0.670 |
Why?
|
| Pneumonia, Mycoplasma | 1 | 2020 | 9 | 0.670 |
Why?
|
| Ear Neoplasms | 1 | 2020 | 13 | 0.670 |
Why?
|
| Mucositis | 1 | 2020 | 18 | 0.670 |
Why?
|
| Margins of Excision | 1 | 2020 | 42 | 0.670 |
Why?
|
| Certification | 1 | 2020 | 65 | 0.670 |
Why?
|
| Private Practice | 1 | 2020 | 11 | 0.660 |
Why?
|
| Coronavirus | 1 | 2020 | 18 | 0.650 |
Why?
|
| Career Mobility | 1 | 2020 | 38 | 0.650 |
Why?
|
| Hyperpigmentation | 2 | 2017 | 6 | 0.650 |
Why?
|
| Low-Level Light Therapy | 1 | 2019 | 15 | 0.640 |
Why?
|
| SEER Program | 4 | 2021 | 229 | 0.640 |
Why?
|
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2019 | 4 | 0.640 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 542 | 0.630 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2019 | 23 | 0.630 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2022 | 221 | 0.630 |
Why?
|
| Silicone Gels | 1 | 2019 | 3 | 0.630 |
Why?
|
| Bacteremia | 1 | 2020 | 105 | 0.620 |
Why?
|
| Sarcoma, Kaposi | 1 | 2019 | 18 | 0.620 |
Why?
|
| Herpes Simplex | 1 | 2020 | 202 | 0.600 |
Why?
|
| Eyelids | 2 | 2016 | 24 | 0.590 |
Why?
|
| MicroRNAs | 2 | 2021 | 576 | 0.590 |
Why?
|
| Antineoplastic Agents | 3 | 2024 | 2366 | 0.590 |
Why?
|
| Pemphigoid, Benign Mucous Membrane | 1 | 2018 | 6 | 0.580 |
Why?
|
| Pandemics | 2 | 2023 | 807 | 0.570 |
Why?
|
| Pain | 2 | 2019 | 406 | 0.560 |
Why?
|
| Skin Diseases, Infectious | 1 | 2017 | 12 | 0.560 |
Why?
|
| Mouth Neoplasms | 1 | 2019 | 198 | 0.530 |
Why?
|
| Licensure, Medical | 3 | 2021 | 22 | 0.530 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1150 | 0.500 |
Why?
|
| Dermatologic Agents | 2 | 2017 | 75 | 0.500 |
Why?
|
| United States | 7 | 2022 | 7367 | 0.490 |
Why?
|
| Immunosuppressive Agents | 2 | 2017 | 989 | 0.470 |
Why?
|
| Pityriasis Rubra Pilaris | 2 | 2019 | 3 | 0.470 |
Why?
|
| Aspergillosis | 1 | 2015 | 39 | 0.470 |
Why?
|
| Blepharoplasty | 1 | 2015 | 8 | 0.470 |
Why?
|
| Opportunistic Infections | 1 | 2015 | 60 | 0.470 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 329 | 0.460 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 315 | 0.460 |
Why?
|
| Biological Products | 1 | 2017 | 171 | 0.460 |
Why?
|
| Patient Compliance | 1 | 2016 | 236 | 0.450 |
Why?
|
| Asthma | 1 | 2022 | 1004 | 0.450 |
Why?
|
| Photoacoustic Techniques | 2 | 2024 | 7 | 0.440 |
Why?
|
| Condylomata Acuminata | 1 | 2014 | 15 | 0.440 |
Why?
|
| Aged | 12 | 2024 | 19953 | 0.430 |
Why?
|
| Sweet Syndrome | 2 | 2014 | 6 | 0.430 |
Why?
|
| Male | 22 | 2024 | 43929 | 0.420 |
Why?
|
| Alphapapillomavirus | 1 | 2014 | 44 | 0.420 |
Why?
|
| Skin Pigmentation | 3 | 2024 | 34 | 0.420 |
Why?
|
| Female | 24 | 2024 | 47901 | 0.410 |
Why?
|
| Epidermis | 3 | 2024 | 102 | 0.400 |
Why?
|
| Middle Aged | 14 | 2024 | 27045 | 0.390 |
Why?
|
| Diagnosis, Differential | 4 | 2019 | 1593 | 0.360 |
Why?
|
| Tomography, Optical Coherence | 4 | 2024 | 149 | 0.340 |
Why?
|
| Infant | 3 | 2022 | 3206 | 0.340 |
Why?
|
| Treatment Outcome | 7 | 2024 | 8730 | 0.330 |
Why?
|
| Esthetics | 3 | 2021 | 49 | 0.330 |
Why?
|
| Antiviral Agents | 1 | 2014 | 498 | 0.330 |
Why?
|
| Cicatrix | 2 | 2024 | 71 | 0.330 |
Why?
|
| Retrospective Studies | 5 | 2022 | 9694 | 0.320 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 6918 | 0.320 |
Why?
|
| Hand Dermatoses | 1 | 2009 | 9 | 0.310 |
Why?
|
| Heart Transplantation | 1 | 2015 | 774 | 0.310 |
Why?
|
| Dermis | 1 | 2009 | 28 | 0.310 |
Why?
|
| Sarcoidosis | 2 | 2020 | 72 | 0.310 |
Why?
|
| Ultraviolet Therapy | 1 | 2009 | 16 | 0.310 |
Why?
|
| Rare Diseases | 2 | 2019 | 71 | 0.300 |
Why?
|
| Biopsy, Needle | 2 | 2019 | 229 | 0.300 |
Why?
|
| Carcinoma, Basal Cell | 2 | 2024 | 62 | 0.280 |
Why?
|
| Color | 2 | 2019 | 86 | 0.270 |
Why?
|
| Curriculum | 2 | 2021 | 584 | 0.260 |
Why?
|
| Administration, Topical | 2 | 2018 | 97 | 0.250 |
Why?
|
| Severity of Illness Index | 3 | 2023 | 1920 | 0.240 |
Why?
|
| Survival Rate | 2 | 2020 | 1926 | 0.240 |
Why?
|
| Cosmetic Techniques | 2 | 2016 | 28 | 0.240 |
Why?
|
| Erythema | 3 | 2022 | 30 | 0.230 |
Why?
|
| Age Factors | 2 | 2019 | 1904 | 0.230 |
Why?
|
| Biomarkers | 3 | 2021 | 1847 | 0.230 |
Why?
|
| Infant, Newborn | 2 | 2022 | 2506 | 0.220 |
Why?
|
| Adult | 11 | 2024 | 27547 | 0.220 |
Why?
|
| Striae Distensae | 1 | 2024 | 1 | 0.220 |
Why?
|
| Anti-Bacterial Agents | 2 | 2022 | 808 | 0.220 |
Why?
|
| Administration, Cutaneous | 1 | 2024 | 61 | 0.220 |
Why?
|
| Patient Care | 1 | 2024 | 103 | 0.200 |
Why?
|
| Health Literacy | 1 | 2024 | 73 | 0.200 |
Why?
|
| Video Recording | 1 | 2024 | 204 | 0.200 |
Why?
|
| Child | 5 | 2022 | 7309 | 0.200 |
Why?
|
| Retinoids | 1 | 2022 | 18 | 0.200 |
Why?
|
| Varicose Ulcer | 1 | 2022 | 6 | 0.200 |
Why?
|
| Purpura | 2 | 2000 | 13 | 0.200 |
Why?
|
| Biopsy | 3 | 2023 | 1194 | 0.200 |
Why?
|
| Phenols | 1 | 2022 | 42 | 0.200 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 1733 | 0.190 |
Why?
|
| Hidradenitis | 1 | 2021 | 2 | 0.180 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2021 | 13 | 0.180 |
Why?
|
| Communicable Diseases | 1 | 2022 | 65 | 0.180 |
Why?
|
| Incidence | 2 | 2023 | 1661 | 0.180 |
Why?
|
| Ultrasonography | 1 | 2024 | 708 | 0.180 |
Why?
|
| Insulin Resistance | 2 | 2021 | 375 | 0.180 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2024 | 462 | 0.180 |
Why?
|
| Bronchogenic Cyst | 1 | 2021 | 5 | 0.180 |
Why?
|
| Dermoid Cyst | 1 | 2021 | 15 | 0.180 |
Why?
|
| Dermoscopy | 1 | 2020 | 6 | 0.180 |
Why?
|
| Up-Regulation | 2 | 2021 | 726 | 0.170 |
Why?
|
| Mycoplasma pneumoniae | 1 | 2020 | 7 | 0.170 |
Why?
|
| Ear, External | 1 | 2020 | 25 | 0.170 |
Why?
|
| Staphylococcus epidermidis | 1 | 2020 | 16 | 0.170 |
Why?
|
| Accreditation | 1 | 2020 | 62 | 0.170 |
Why?
|
| Necrobiosis Lipoidica | 1 | 2020 | 2 | 0.170 |
Why?
|
| Personnel Selection | 1 | 2020 | 62 | 0.170 |
Why?
|
| Necrosis | 3 | 2015 | 209 | 0.160 |
Why?
|
| Mannose-Binding Lectins | 1 | 2019 | 6 | 0.160 |
Why?
|
| Tattooing | 1 | 2019 | 5 | 0.160 |
Why?
|
| Mutagens | 1 | 2019 | 30 | 0.160 |
Why?
|
| Mice, Transgenic | 2 | 2021 | 1593 | 0.160 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2021 | 275 | 0.160 |
Why?
|
| Panuveitis | 1 | 2019 | 4 | 0.160 |
Why?
|
| Mastocytoma, Skin | 1 | 2019 | 1 | 0.160 |
Why?
|
| Protective Factors | 1 | 2019 | 26 | 0.160 |
Why?
|
| Mastocytoma | 1 | 2019 | 4 | 0.160 |
Why?
|
| Lupus Vulgaris | 1 | 2019 | 4 | 0.160 |
Why?
|
| Corneal Ulcer | 1 | 2019 | 7 | 0.160 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 1 | 2019 | 4 | 0.160 |
Why?
|
| Scleritis | 1 | 2019 | 6 | 0.160 |
Why?
|
| Cultural Diversity | 1 | 2020 | 60 | 0.160 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2019 | 6 | 0.160 |
Why?
|
| S100 Proteins | 1 | 2019 | 53 | 0.160 |
Why?
|
| Antigens, CD1 | 1 | 2019 | 37 | 0.160 |
Why?
|
| Paraproteinemias | 1 | 2019 | 17 | 0.160 |
Why?
|
| Interviews as Topic | 1 | 2020 | 351 | 0.160 |
Why?
|
| Lectins, C-Type | 1 | 2019 | 87 | 0.160 |
Why?
|
| Simplexvirus | 1 | 2020 | 152 | 0.150 |
Why?
|
| Arthralgia | 1 | 2019 | 41 | 0.150 |
Why?
|
| Antigen-Antibody Complex | 1 | 2019 | 88 | 0.150 |
Why?
|
| Medicare | 1 | 2022 | 440 | 0.150 |
Why?
|
| Microscopy, Electron | 1 | 2019 | 509 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 863 | 0.150 |
Why?
|
| Minority Groups | 1 | 2020 | 151 | 0.150 |
Why?
|
| Vascular Diseases | 1 | 2000 | 120 | 0.150 |
Why?
|
| Anesthetics, Local | 1 | 2019 | 82 | 0.150 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2018 | 30 | 0.150 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 236 | 0.140 |
Why?
|
| Tumor Burden | 1 | 2019 | 314 | 0.140 |
Why?
|
| Neoplasm Proteins | 1 | 2021 | 547 | 0.140 |
Why?
|
| Pain Management | 1 | 2019 | 154 | 0.140 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2017 | 8 | 0.140 |
Why?
|
| Keratinocytes | 1 | 2018 | 147 | 0.140 |
Why?
|
| Wound Healing | 2 | 2019 | 371 | 0.140 |
Why?
|
| Antigens, CD | 1 | 2019 | 473 | 0.140 |
Why?
|
| Lymphatic Metastasis | 1 | 2019 | 498 | 0.140 |
Why?
|
| Telemedicine | 1 | 2020 | 213 | 0.140 |
Why?
|
| Dermatitis, Phototoxic | 1 | 1997 | 2 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 597 | 0.140 |
Why?
|
| Neutrophils | 3 | 2021 | 323 | 0.130 |
Why?
|
| Motivation | 1 | 2020 | 309 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 270 | 0.130 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 1773 | 0.130 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 871 | 0.130 |
Why?
|
| Positron-Emission Tomography | 1 | 2019 | 342 | 0.130 |
Why?
|
| Immunity, Cellular | 1 | 2017 | 184 | 0.130 |
Why?
|
| Hospitalization | 1 | 2022 | 925 | 0.130 |
Why?
|
| Nocardia Infections | 1 | 2016 | 5 | 0.130 |
Why?
|
| Onychomycosis | 1 | 2016 | 1 | 0.130 |
Why?
|
| Intense Pulsed Light Therapy | 1 | 2016 | 1 | 0.130 |
Why?
|
| Doxycycline | 1 | 2016 | 30 | 0.130 |
Why?
|
| Telangiectasis | 1 | 2016 | 8 | 0.130 |
Why?
|
| Biomedical Research | 1 | 2020 | 407 | 0.130 |
Why?
|
| Hirsutism | 1 | 2016 | 61 | 0.120 |
Why?
|
| Logistic Models | 2 | 2019 | 1239 | 0.120 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 2730 | 0.120 |
Why?
|
| Sex Factors | 1 | 2019 | 1094 | 0.120 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 413 | 0.120 |
Why?
|
| Clinical Competence | 1 | 2021 | 809 | 0.120 |
Why?
|
| Fluorouracil | 1 | 2017 | 549 | 0.120 |
Why?
|
| Cosmetics | 1 | 2015 | 7 | 0.120 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2021 | 816 | 0.120 |
Why?
|
| Life Change Events | 1 | 2015 | 48 | 0.110 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 1804 | 0.110 |
Why?
|
| Cellulitis | 1 | 2014 | 19 | 0.110 |
Why?
|
| Injections, Intralesional | 1 | 2014 | 21 | 0.110 |
Why?
|
| Caustics | 1 | 2014 | 4 | 0.110 |
Why?
|
| Cryotherapy | 1 | 2014 | 30 | 0.110 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 2450 | 0.100 |
Why?
|
| Metabolic Syndrome | 1 | 2015 | 127 | 0.100 |
Why?
|
| Prognosis | 1 | 2021 | 3872 | 0.100 |
Why?
|
| Animals | 7 | 2024 | 28059 | 0.100 |
Why?
|
| Child Development | 1 | 2015 | 168 | 0.100 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2015 | 120 | 0.100 |
Why?
|
| Muir-Torre Syndrome | 1 | 2012 | 5 | 0.100 |
Why?
|
| Risk Factors | 4 | 2019 | 5708 | 0.100 |
Why?
|
| Facial Neoplasms | 1 | 2012 | 26 | 0.100 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2019 | 609 | 0.100 |
Why?
|
| Inflammation | 1 | 2018 | 1024 | 0.100 |
Why?
|
| Viral Proteins | 1 | 2014 | 286 | 0.100 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2015 | 275 | 0.100 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 1573 | 0.100 |
Why?
|
| Patient Selection | 1 | 2016 | 689 | 0.100 |
Why?
|
| Young Adult | 1 | 2024 | 6629 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2019 | 2368 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 2555 | 0.090 |
Why?
|
| Physician-Patient Relations | 1 | 2016 | 630 | 0.090 |
Why?
|
| Adenoma | 1 | 2012 | 254 | 0.080 |
Why?
|
| HIV Infections | 1 | 2019 | 896 | 0.080 |
Why?
|
| Signal Transduction | 1 | 2021 | 3505 | 0.080 |
Why?
|
| Mice | 2 | 2021 | 12133 | 0.080 |
Why?
|
| Genotype | 1 | 2014 | 1865 | 0.080 |
Why?
|
| Rabbits | 3 | 2000 | 645 | 0.080 |
Why?
|
| Adolescent | 3 | 2017 | 9495 | 0.080 |
Why?
|
| Puerperal Disorders | 1 | 2009 | 37 | 0.070 |
Why?
|
| Obesity | 2 | 2015 | 1014 | 0.070 |
Why?
|
| Down-Regulation | 2 | 2021 | 523 | 0.070 |
Why?
|
| Dermatofibrosarcoma | 1 | 2008 | 14 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 742 | 0.070 |
Why?
|
| Porphyrins | 2 | 1998 | 39 | 0.070 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 760 | 0.070 |
Why?
|
| Kidney Transplantation | 1 | 2012 | 863 | 0.060 |
Why?
|
| Apoptosis | 2 | 2021 | 1737 | 0.050 |
Why?
|
| Hemoglobins | 1 | 2024 | 191 | 0.050 |
Why?
|
| Support Vector Machine | 1 | 2023 | 23 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2021 | 1900 | 0.050 |
Why?
|
| Ulcer | 1 | 2022 | 38 | 0.050 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2000 | 188 | 0.050 |
Why?
|
| Burns | 1 | 2024 | 145 | 0.050 |
Why?
|
| Hair Removal | 1 | 2002 | 14 | 0.050 |
Why?
|
| Sweat Glands | 1 | 2021 | 6 | 0.050 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2021 | 41 | 0.050 |
Why?
|
| Cold Temperature | 1 | 2002 | 161 | 0.050 |
Why?
|
| Daunorubicin | 1 | 2021 | 78 | 0.050 |
Why?
|
| Mercaptopurine | 1 | 2021 | 53 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2024 | 1232 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2024 | 902 | 0.040 |
Why?
|
| Leg Ulcer | 1 | 2001 | 7 | 0.040 |
Why?
|
| Cytarabine | 1 | 2021 | 222 | 0.040 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2001 | 19 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2021 | 304 | 0.040 |
Why?
|
| Ischemia | 1 | 2022 | 254 | 0.040 |
Why?
|
| Pruritus | 1 | 2000 | 29 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2001 | 241 | 0.040 |
Why?
|
| Blood Vessels | 1 | 2000 | 92 | 0.040 |
Why?
|
| Software | 1 | 2024 | 677 | 0.040 |
Why?
|
| Skin Transplantation | 1 | 2001 | 192 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2024 | 470 | 0.040 |
Why?
|
| Lymphangiogenesis | 1 | 2018 | 40 | 0.040 |
Why?
|
| Rats | 1 | 2024 | 4073 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 1398 | 0.030 |
Why?
|
| Maximum Allowable Concentration | 1 | 1997 | 2 | 0.030 |
Why?
|
| Protoporphyrins | 1 | 1997 | 19 | 0.030 |
Why?
|
| Radiation Injuries, Experimental | 1 | 1997 | 41 | 0.030 |
Why?
|
| Fluorescence | 1 | 1997 | 104 | 0.030 |
Why?
|
| Edema | 1 | 1997 | 68 | 0.030 |
Why?
|
| Nocardia | 1 | 2016 | 2 | 0.030 |
Why?
|
| Light | 1 | 1997 | 295 | 0.030 |
Why?
|
| Recurrence | 2 | 2014 | 1180 | 0.030 |
Why?
|
| Algorithms | 1 | 2024 | 1960 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2024 | 4474 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 806 | 0.030 |
Why?
|
| Boston | 1 | 2015 | 36 | 0.030 |
Why?
|
| Time Factors | 3 | 2002 | 5431 | 0.030 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2014 | 28 | 0.030 |
Why?
|
| Quality of Life | 1 | 2023 | 1745 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2024 | 2685 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2015 | 173 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2015 | 799 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1117 | 0.020 |
Why?
|
| Comorbidity | 1 | 2015 | 986 | 0.020 |
Why?
|
| Cholelithiasis | 1 | 1989 | 35 | 0.020 |
Why?
|
| Dietary Fats | 1 | 1989 | 136 | 0.020 |
Why?
|
| Furocoumarins | 1 | 2007 | 2 | 0.020 |
Why?
|
| New Hampshire | 1 | 2007 | 3 | 0.020 |
Why?
|
| Fluoroquinolones | 1 | 2007 | 22 | 0.020 |
Why?
|
| Diet | 1 | 1989 | 448 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 2007 | 196 | 0.020 |
Why?
|
| Trauma Severity Indices | 1 | 2002 | 46 | 0.010 |
Why?
|
| Skin, Artificial | 1 | 2001 | 8 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2008 | 3806 | 0.010 |
Why?
|
| Liposomes | 1 | 1998 | 94 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2001 | 1015 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1998 | 294 | 0.010 |
Why?
|
| Drug Carriers | 1 | 1998 | 82 | 0.010 |
Why?
|
| Iontophoresis | 1 | 1997 | 7 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 1997 | 260 | 0.010 |
Why?
|
| Models, Biological | 1 | 1998 | 1785 | 0.010 |
Why?
|
| Plant Oils | 1 | 1989 | 9 | 0.010 |
Why?
|
| Occupations | 1 | 1989 | 24 | 0.000 |
Why?
|
| Chi-Square Distribution | 1 | 1989 | 359 | 0.000 |
Why?
|
| Smoking | 1 | 1989 | 640 | 0.000 |
Why?
|